ARMP:NYE-Armata Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 4.27

Change

-0.36 (-7.83)%

Market Cap

USD 0.17B

Volume

3.66K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ARMP Stock Forecast & Price:
Based on the Armata Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Armata Pharmaceuticals Inc is not available over the next 12 months. Armata Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Armata Pharmaceuticals Inc is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Armata Pharmaceuticals Inc’s stock price was USD 4.27. Armata Pharmaceuticals Inc’s stock price has changed by -6.21% over the past week, +3.58% over the past month and +17.88% over the last year.

About Armata Pharmaceuticals Inc (ARMP:NYE)

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's prod ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.62 (+0.65%)

USD215.92B 32.65 3.02
BHVN Biohaven Pharmaceutical Holdin..

+0.23 (+0.15%)

USD10.90B N/A -15.30
DNA Ginkgo Bioworks Holdings

+0.09 (+3.21%)

USD5.25B N/A -1.31
RCUS Arcus Biosciences Inc

+1.37 (+5.59%)

USD1.82B 25.21 10.11
MYOV Myovant Sciences Ltd

+0.73 (+4.42%)

USD1.61B N/A -11.99
NUVB Nuvation Bio Inc

+0.09 (+4.33%)

USD0.45B N/A 2.22
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
ADCT Adc Therapeutics SA

+0.16 (+3.43%)

USD0.36B -99,999.99 -0.65
ZYME Zymeworks Inc

+0.24 (+4.55%)

USD0.32B 300.20 -0.50
LCTX Lineage Cell Therapeutics Inc

N/A

USD0.20B 3.63 -2.90

ETFs Containing ARMP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.13% 85% B 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.13% 85% B 47% F
Trailing 12 Months  
Capital Gain 17.88% 100% A+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.88% 100% A+ 93% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 7.53% 68% D+ 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.53% 68% D+ 55% F
Risk Return Profile  
Volatility (Standard Deviation) 24.22% 88% B+ 47% F
Risk Adjusted Return 31.11% 79% C+ 51% F
Market Capitalization 0.17B 72% C- 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.32 42% F 22% F
Price / Cash Flow Ratio -7.10 72% C- 83% B
EV/EBITDA -6.29 94% A 86% B
Management Effectiveness  
Return on Equity -71.92% 47% F 5% F
Return on Invested Capital -105.93% 28% F 3% F
Return on Assets -25.28% 60% D- 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 24.28 6% F 1% F
Short Percent 0.45% 97% A+ 83% B
Beta 0.18 84% B 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.